AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Theglobeandmail

Published November 11, 2026

BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical ...

Read the full story at Theglobeandmail

ACCESS Newswire Press Release ... psychedelic effects, targeting the BDNF/TrkB synaptic repair pathway. In a 2026 Neuropsychopharmacology study.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release